MICHEAL KAISER: Open Payments
NPI 1053037812 · SIERRA VISTA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$461 in 26 payments from 12 companies in 2025. Trend: 2023 $549 · 2024 $629 · 2025 $461
Food & beverage: $461
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 6 | $118 |
| Amgen Inc. | 5 | $84 |
| ABBVIE INC. | 3 | $56 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| Novo Nordisk Inc | 2 | $35 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Abbott Laboratories | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Exact Sciences Corporation | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
Products named: TRELEGY ELLIPTA, VRAYLAR, EVENITY, OTEZLA, ZENPEP, FREESTYLE LIBRE 3, FARXIGA, KISUNLA.
Industry payments across AZ — which companies pay providers there.
